Treatments of AIDS-related Kaposi's sarcoma

Savina Maria Lucia Aversa, Anna Maria Cattelan, Luigi Salvagno, Gino Crivellari, Giuseppe Banna, Marco Trevenzoli, Vanna Chiarion-Sileni, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review


Although Kaposi's sarcoma (KS) has decreased in countries where the highly active antiretroviral therapy (HAART) regimen is available, however it remains, after non-Hodgkin's lymphomas, the most common malignancy in HIV+ patients. Advances in the treatment of AIDS-KS have been achieved, even though a gold standard therapy has not been yet defined. With the availability of HAART, a dramatic KS clinical response has been documented, making HAART essential in all patients. In case of aggressive and/or life threatening KS, more complex therapeutic schedules have to be taken into account, including chemotherapy and/or immunotherapy. Liposomal anthracyclines and paclitaxel have been approved by FDA as first line and second line mono-therapy, respectively. Interferon-alpha (INF-α) is the only immunomodulant agent to have shown a therapeutic effect. Among the new drugs, many antiangiogenetic agents have produced encouraging responses. Finally, the identification of the HHV-8 as a causative agent and new metalloproteinase inhibitors may offer promising targets for the KS treatment.

Original languageEnglish
Pages (from-to)253-265
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - Mar 2005


  • AIDS-related Kaposi's sarcoma
  • Kaposi's sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Treatments of AIDS-related Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this